X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (127) 127
humans (114) 114
female (99) 99
breast neoplasms - drug therapy (64) 64
index medicus (56) 56
breast cancer (54) 54
breast neoplasms - pathology (51) 51
middle aged (40) 40
adult (37) 37
chemotherapy (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
aged (27) 27
treatment outcome (25) 25
therapy (24) 24
cancer (22) 22
neoplasm staging (20) 20
tamoxifen (19) 19
breast neoplasms - therapy (18) 18
chemotherapy, adjuvant (18) 18
medicine & public health (18) 18
care and treatment (17) 17
survival (17) 17
women (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
metastasis (15) 15
neoplasm metastasis (15) 15
postmenopausal women (15) 15
breast neoplasms - metabolism (14) 14
clinical trials (14) 14
drug therapy (14) 14
prognosis (14) 14
randomized-trial (14) 14
antineoplastic agents - therapeutic use (13) 13
breast neoplasms - mortality (13) 13
clinical trials as topic (13) 13
disease-free survival (13) 13
docetaxel (13) 13
surgical adjuvant breast (13) 13
aromatase inhibitors (12) 12
capecitabine (12) 12
paclitaxel - administration & dosage (12) 12
receptor, erbb-2 - metabolism (12) 12
trial (12) 12
antineoplastic agents - adverse effects (11) 11
double-blind (11) 11
endocrine therapy (11) 11
male (11) 11
medicine, general & internal (11) 11
phase-iii trial (11) 11
survival analysis (11) 11
1st-line treatment (10) 10
article (10) 10
metastatic breast cancer (10) 10
research (10) 10
risk factors (10) 10
trastuzumab (10) 10
aged, 80 and over (9) 9
carcinoma (9) 9
first-line therapy (9) 9
hematology, oncology and palliative medicine (9) 9
paclitaxel (9) 9
receptor, erbb-2 - antagonists & inhibitors (9) 9
taxoids - administration & dosage (9) 9
adjuvant chemotherapy (8) 8
animals (8) 8
breast neoplasms - surgery (8) 8
combined modality therapy (8) 8
drug administration schedule (8) 8
hematology (8) 8
open-label (8) 8
phase-ii (8) 8
phase-iii (8) 8
united states (8) 8
albumin-bound paclitaxel (7) 7
analysis (7) 7
antineoplastic agents (7) 7
antineoplastic agents - pharmacology (7) 7
antineoplastic agents, hormonal - therapeutic use (7) 7
bone-mineral density (7) 7
breast-cancer (7) 7
doxorubicin (7) 7
efficacy (7) 7
infusions, intravenous (7) 7
kaplan-meier estimate (7) 7
molecular targeted therapy (7) 7
neoadjuvant therapy (7) 7
pharmacology & pharmacy (7) 7
phase-i (7) 7
randomized trial (7) 7
survival rate (7) 7
adenocarcinoma - drug therapy (6) 6
advanced breast-cancer (6) 6
american-society (6) 6
anastrozole (6) 6
anthracycline (6) 6
antimitotic agents (6) 6
bevacizumab (6) 6
breast neoplasms - diagnosis (6) 6
breast neoplasms - prevention & control (6) 6
cyclophosphamide (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2017, Volume 15, Issue 5.5, pp. 679 - 681
The management of advanced hormone receptor positive disease has evolved with the emergence of CDK4/6 inhibitors. Improvements in progression-free survival of... 
PALBOCICLIB | WOMEN | ONCOLOGY | LETROZOLE | INHIBITOR
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 06/2006, Volume 7, Issue 8, pp. 1041 - 1053
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2014, Volume 12, Issue 5.5, pp. 759 - 761
Many newer agents in combination are being studied in the front-line treatment of women with HER2-positive metastatic breast cancer (MBC), but the story in the... 
TRIAL | PLACEBO | EXEMESTANE | ONCOLOGY | FULVESTRANT | COMBINATION | AROMATASE INHIBITORS | ANASTROZOLE
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2015, Volume 13, Issue 5.5, pp. 649 - 651
The treatment of HER2-positive breast cancer has benefited from a number of targeted agents. Although adjuvant trastuzumab has dramatically reduced progression... 
WOMEN | TRASTUZUMAB | ONCOLOGY
Journal Article
Cancer Management and Research, ISSN 1179-1322, 07/2016, Volume 2016, Issue Issue 1, pp. 85 - 94
William J Gradishar Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Abstract:... 
endocrine resistance | hormone receptor-positive advanced breast cancer | community oncologists
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 08/2012, Volume 21, Issue 8, pp. 1177 - 1191
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 10/2018, Volume 23, Issue 10, pp. 1153 - 1161
Anthracyclines have been a mainstay of breast cancer therapy for decades, with strong evidence demonstrating their impact on breast cancer survival. However,... 
Anthracycline | Adjuvant chemotherapy | Breast cancer | CARDIAC SAFETY | TOPOISOMERASE-II | RISK-FACTORS | HEART-FAILURE | RANDOMIZED-TRIAL | FOLLOW-UP | PREMENOPAUSAL WOMEN | MYELODYSPLASTIC SYNDROME | ONCOLOGY | COMBINATION CHEMOTHERAPY | RETROSPECTIVE ANALYSIS | Index Medicus | Breast Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 8, pp. 725 - 727
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 03/2016, Volume 14, Issue 3, pp. 324 - 354
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management... 
POSTMASTECTOMY RADIATION IMPROVES | FERTILITY PRESERVATION | SKIN-SPARING MASTECTOMY | LUMPECTOMY PLUS TAMOXIFEN | ONCOLOGY | SENTINEL-NODE BIOPSY | CONTRALATERAL PROPHYLACTIC MASTECTOMY | RANDOMIZED CONTROLLED-TRIAL | CONSERVING THERAPY | 20-YEAR FOLLOW-UP | AMERICAN-SOCIETY
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 05/2018, Volume 16, Issue 5S, pp. 605 - 610
The emergence of CDK4/6 inhibitors has changed the treatment algorithm for advanced/metastatic estrogen receptor-positive breast cancer. In pivotal trials of... 
TRASTUZUMAB | ONCOLOGY | DOUBLE-BLIND | ENDOCRINE THERAPY | ANTIBODY | CONJUGATE GLEMBATUMUMAB VEDOTIN | ADJUVANT THERAPY
Journal Article